QT Imaging Announces Presentation at SPIE Medical Imaging 2026

Key Terms

breast acoustic ct medical

Breast acoustic CT is a medical imaging method that uses sound waves sent around the breast to build a three‑dimensional map of tissue characteristics—think of it like sonar creating a detailed picture of internal structure. It matters to investors because it can change the competitive landscape for breast screening and diagnostics: differences in accuracy, safety, regulatory approval, and reimbursement can affect how widely the technology is adopted and the commercial prospects for companies that develop or sell it.

reflection data technical

Reflection data are measurements captured from signals (light, sound, radio waves or similar) that bounce off an object or sample and return to a sensor; think of using an echo or flashlight beam to learn the shape or surface of something. For investors, these measurements matter because they provide objective evidence about product performance, quality control, regulatory compliance, or technical feasibility—information that can affect a company’s risk profile, claims, and market value.

ai/ml technical

AI/ML stands for artificial intelligence and machine learning, software systems that identify patterns in data and make predictions or automate decisions, improving performance as they process more information. Investors care because these technologies can boost revenue, cut costs and create competitive advantages — like a factory that learns to produce goods faster and with fewer mistakes — while also introducing execution, ethical and regulatory risks that can affect a company’s value.

nonlinear optimization technical

A mathematical process for finding the best solution when relationships between variables curve or bend rather than form straight lines, like choosing settings that maximize return or minimize risk when outcomes interact in complex ways. It matters to investors because many real-world problems—building a portfolio, pricing assets, or managing risk—are nonlinear, so this approach helps find more realistic, often better decisions under limits and trade‑offs, similar to picking the fastest path through hilly terrain instead of assuming flat ground.

denoising technical

Denoising is the process of removing irrelevant or misleading random variations from data so the underlying pattern becomes clearer, like wiping a smudged window to see the view. For investors, denoising makes price charts, financial reports, or medical measurements easier to interpret, reducing false alarms and improving the reliability of models and forecasts used to value assets or assess risk.

multi-step algorithm technical

A multi-step algorithm is a programmed set of ordered actions that takes data in, applies several processing or decision stages, and produces an output or recommendation. Think of it like a recipe where each step transforms ingredients toward a final dish. Investors care because the design and sequence of steps determine speed, accuracy, and bias of automated analyses or trading signals, affecting performance, risk and regulatory transparency.

lesion segmentation medical

Lesion segmentation is the process of automatically or manually marking and measuring abnormal areas—such as tumors, scars, or infections—on medical images so each affected spot is identified and separated from healthy tissue. Like using a highlighter to outline objects in a photo, it turns visual findings into precise measurements and maps; this matters to investors because it drives the accuracy of diagnostics, determines trial outcomes, influences regulatory approval, and underpins the value of imaging technologies and AI products.

clinical decision support tools medical

Software or systems that give doctors and healthcare teams timely, evidence-based recommendations or alerts to help diagnose, treat, or manage patients — like a GPS that guides clinical decisions by matching patient data to medical knowledge. Investors care because these tools can speed care, reduce errors, lower costs, and create recurring software revenue, but their value depends on clinical adoption, regulatory approval, integration with hospital systems, and data accuracy.

NOVATO, Calif.--(BUSINESS WIRE)-- QT Imaging Holdings, Inc. (NASDAQ: QTI) (“QT Imaging” or the “Company”), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, is pleased to announce that its Chief Science Officer, Bilal Malik, Ph.D., will present at the prestigious International Society for Optics & Photonics (“SPIE”) Medical Imaging meeting taking place in Vancouver, BC, Canada, from February 15–19, 2026.

SPIE Medical Imaging 2026 is a premier international symposium focusing on the latest research in medical image processing, physics, and computer-aided diagnosis. The event, which is in its 50th year, covers advancements in AI, ultrasound, digital pathology, and image-guided procedures.

In his oral presentation, titled “Automated breast boundary extraction from reflection data in breast acoustic CT,” Dr. Malik will highlight an automated method to accurately define the breast boundary in QT Imaging Breast Acoustic CT™ scans, a critical step in image formation and analysis. The work reflects QT Imaging’s broader strategy to combine advanced physics-based imaging with modern artificial intelligence and machine learning (AI/ML) tools to enhance clinical utility.

“Accurate breast boundary detection guides the nonlinear optimization for image reconstructions, determines the gain factor for reflection imaging, enables water-region denoising, supports calculation of breast density, and enhances the robustness of QT Imaging’s reconstruction pipeline,” said Dr. Malik.

“We developed a multi-step algorithm that extracts the breast boundary from reflection data by detecting primary reflection events, refining them through filtering and interpolation, and compensating for missing data near the chest wall via extrapolation. This algorithm is fast, validated on a large dataset, and fully integrated into QT Imaging’s production software, underscoring the maturity of the technology.”

This work also serves as a foundation for QT Imaging’s planned AI/ML initiatives, including automated lesion segmentation and clinical decision support tools. By pairing precise boundary detection with advanced machine learning, the Company aims to improve lesion characterization, streamline clinical workflows, and provide clinicians with more actionable insights from each scan.

About QT Imaging Holdings, Inc.

QT Imaging Holdings, Inc. is a public (NASDAQ: QTI) medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience. For more information on QT Imaging Holdings, Inc., please visit the Company’s website at www.qtimaging.com.

Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as “will,” and “expect,” or the negative thereof or comparable terminology, and include (without limitation) statements regarding the upcoming presentation and the planned AI/ML initiatives, new product development and introduction, and product sales growth and projected revenues. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These risks include, but are not limited to: research results from the use of the QTI Breast Acoustic CT scanner, clinical studies, the ability of QT Imaging to sell and deploy the QTI Breast Acoustic CT scanner, the ability to extend product offerings into new areas or products, the ability to commercialize technology, unexpected occurrences that deter the full documentation and “bring to market” plan for products, trends and fluctuations in the industry, changes in demand and purchasing volume of customers, unpredictability of suppliers, the ability to attract and retain qualified personnel and the ability to move product sales to production levels. Additional factors that could cause actual results to differ are discussed under the heading “Risk Factors” and in other sections of QT Imaging Holding’s filings with the SEC, and in its other current and periodic reports filed or furnished from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to QT Imaging Holdings as of the date hereof, and QT Imaging Holdings assumes no obligation to update any forward-looking statement.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260203862234/en/

For media inquiries, please contact:



Stephen Kilmer

Head of Investor Relations

Stephen.Kilmer@qtimaging.com

Direct: (646) 274-3580

Source: QT Imaging Holdings, Inc.